Golden
Codexis

Codexis

An enzyme engineering company supplying products to commercial customers and developing proteins for its own portfolio of clinical biologics.

Codexis was incorporated in 2002 by Maxygen to develop an enzyme engineering technology platform, completing a spin-off in 2010 as a separate publicly-listed company on the NASDAQ exchange. Today it has three major focus areas: supplying engineered enzymes to commercial customers in pharmaceutical manufacturing, food ingredient manufacturing, and other industrial areas; licensing its CodeEvolver technology package to companies interested in engineering enzymes in-house; and developing a clinical portfolio of biologics created from its technology platform. In 2018 the company expects to generate $60 million to $63 million in revenue for the full year, including $25 million to $28 million from products in commercial supply contracts.

Timeline

People

Name
Role
Related Golden topics

Adam Litle

Employee

Barry Ettenger

Employee

Brian Kirshner

Employee

Christopher McCarthy

Employee

Darla Llewelyn

Employee

David J. Galgoczy

Employee

David McCaman, CPA

Employee

Dayna H. Johnson

Employee

Diana Maichin

Employee

Gordon Sangster

Senior Vice President, CFO

Gregg Ringold

Employee

Gregory Miller

Employee

Jim Lalonde

Senior Vice President of R&D

John Nichols

President, CEO

John Vu

Employee

Joshua Geilhufe

Employee

Kamrin Mac Knight

Employee

Kiyoung Paik

Employee

Lana Spencer, PG, CHMM, QISP

Advisor

Lisa Moore

Employee

Lucia Guh-Siesel

Attorney

Melvina Ho

Employee

Michael Aldridge

Corporate and Strategic Development

Monica Bhatia

Employee

Navneet Chagger

Employee

SHOW ALL (31)

Further reading

Title
Author
Link
Type

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services